GlassScriptPhysician profile
Dustin M Snelling
NPI 1174501043
$3,733.07
in general payments reported to CMS, 2019-2025
36 companies · $377 in 2025
The $377 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,005 · 2020: $571 · 2021: $477 · 2022: $399 · 2023: $443 · 2024: $460 · 2025: $377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,280.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $393.29 | 2019-2025 | Evenity, Otezla, Repatha |
| Merck Sharp & Dohme LLC | $362.69 | 2019-2024 | Vaxelis, Gardasil 9, Vaxneuvance |
| Novo Nordisk INC | $321.19 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $292.00 | 2021-2025 | Ubrelvy, Vraylar, Linzess |
| Astrazeneca Pharmaceuticals LP | $270.97 | 2019-2024 | Airsupra, Farxiga |
| Lilly USA, LLC | $264.59 | 2019-2025 | Mounjaro, Zepbound |
| Astellas Pharma US INC | $211.23 | 2019-2024 | Veozah |
| Pfizer INC. | $203.69 | 2019-2024 | |
| Sunovion Pharmaceuticals INC. | $170.64 | 2019 | |
| Janssen Pharmaceuticals, INC | $146.40 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $127.37 | 2019-2023 | Austedo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.77 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $87.90 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $80.16 | 2024-2025 | Voquezna |
| Glaxosmithkline, LLC. | $79.54 | 2020-2023 | Arexvy |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $72.97 | 2020-2024 | Injectafer |
| Amarin Pharma, INC. | $59.22 | 2020-2021 | |
| Allergan, INC. | $52.73 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $44.70 | 2021-2024 | Eliquis |
| Grifols USA, LLC | $42.10 | 2019-2020 | |
| Eisai INC. | $30.39 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $28.85 | 2024-2025 | Opsumit, Uptravi |
| Viatris Specialty LLC | $28.46 | 2025 | Yupelri |
| Idorsia Pharmaceuticals US INC | $27.82 | 2023 | Quviviq |
| Dynavax Technologies Corporation | $27.64 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $18.93 | 2019 | |
| Medtronic, INC. | $18.15 | 2023 | Minimed 780g |
| Biohaven Pharmaceuticals, INC. | $17.66 | 2021 | |
| Abbott Laboratories | $17.52 | 2021 | |
| Inspire Medical Systems, INC. | $17.35 | 2025 | Inspire |
| Insmed, INC. | $16.63 | 2025 | Arikayce |
| Impel Pharmaceuticals INC. | $15.18 | 2023 | Trudhesa |
| Mylan Specialty L.P. | $14.89 | 2023 | Yupelri |
| Biohaven Pharmaceutical Holding Company LTD. | $14.81 | 2022 | |
| Almatica Pharma LLC | $14.53 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.11 | 2023 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dustin Snelling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.